Extracellular matrix turnover and signaling during cardiac remodeling following MI: Causes and consequences

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 3, 2010, Pages 558-563

  Zamilpa, Rogelio ^a   Lindsey, Merry L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Extracellular matrix; Fibroblasts; Left ventricular remodeling; Macrophages; Matricryptins; Matrix metalloproteinases; Myocardial infarction; Review

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COLLAGEN; INTEGRIN; MATRIX METALLOPROTEINASE; PROTEINASE; SCLEROPROTEIN;

CELL METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE MUTATION; GENE SYNTHESIS; HEART INFARCTION; HEART MUSCLE FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EXTRACELLULAR MATRIX; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 77649270132     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.06.012     Document Type: Review

References (58)

1. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 2000, 35(3):569-582.
2. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
3. Lindsey M.L. MMP induction and inhibition in myocardial infarction. Heart Fail. Rev. 2004 Jan, 9(1):7-19.
4. Banerjee I., Yekkala K., Borg T.K., Baudino T.A. Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Ann. N. Y. Acad. Sci. 2006 Oct, 1080:76-84.
5. Sundstrom J., Vasan R.S. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr. Opin. Lipidol. 2006 Feb, 17(1):45-53.
6. Lambert J.M., Lopez E.F., Lindsey M.L. Macrophage roles following myocardial infarction. Int. J. Cardiol. 2008 Nov 12, 130(2). 147-58.
7. Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol. 2008 April 15, 2008;180(8):5707-19.
8. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, Bruce JA, et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006 June 27, 2006;113(25):2919-28.
9. Peterson J.T., Li H., Dillon L., Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc. Res. 2000, 46:307-315.
10. Krishnamurthy P., Peterson J., Subramanian V., Singh M., Singh K. Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol. Cell. Biochem. 2009, 322(1):53-62.
11. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001, 103:2181-2187.
12. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 15(23):3063-3070.
13. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation. 2003 September 23, 2003; 108(12): 1487-92.
14. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 January 1, 2006;290(1):H232-9.
15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003 April 1, 2003;107(12):1579-85.
16. Horne B.D., Camp N.J., Carlquist J.F., Muhlestein J.B., Kolek M.J., Nicholas Z.P., et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am. Heart J. 2007 Oct, 154(4):751-758.
17. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008 September 1, 2008; 29(17):2116-24.
18. Kolaczkowska E., Chadzinska M., Scislowska-Czarnecka A., Plytycz B., Opdenakker G., Arnold B. Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. Immunobiology 2006, 211(3):137-148.
19. Porter S., Clark I.M., Kevorkian L., Edwards D.R. The ADAMTS metalloproteinases. Biochem. J. 2005 Feb 15, 386(Pt 1):15-27.
20. Manso A.M., Elsherif L., Kang S.-M., Ross R.S. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc. Res. 2006, 69(3):574-584.
21. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev., Cancer. 2008, 8(12):932-941.
22. Maquart F-X, Pasco S, Ramont L, Hornebeck W, Monboisse J-C. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity: implication in tumor invasion. Critical Reviews in Oncology/Hematology. 2004 2004/3;49(3):199-202.
23. Schellings MWM, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovascular Research. 2004 2004/10/1;64(1):24-31.
24. Sternlicht M., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17(1):463-516.
25. Sasaki T., Gohring W., Mann K., Maurer P., Hohenester E., Knauper V., et al. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem. 1997 Apr 4, 272(14):9237-9243.
26. Diez J., Panizo A., Gil M.J., Monreal I., Hernandex M., Mindan J.P. Serum markers of collagen type i metabolism in spontaneously hypertensive rats. Circulation 1996, 93:1026-1032.
27. McGavigan A.D., Maxwell P.R., Dunn F.G. Serological evidence of altered collagen homeostasis reflects early ventricular remodeling following acute myocardial infarction. Int. J. Cardiol. 2006, 111(2):267-274.
28. Villarreal F., Omens J., Dillmann W., Risteli J., Nguyen J., Covell J. Early degradation and serum appearance of type I collagen fragments after myocardial infarction. J. Mol. Cell. Cardiol. 2004, 36(4):597-601.
29. Radovan J., Vaclav P., Petr W., Jan C., Michal A., Richard P., et al. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol. Cell. Biochem. 2006, 293(1):71-78.
30. Bellon G, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Critical Reviews in Oncology/Hematology. 2004 2004/3;49(3):203-20.
31. Pasco S, Ramont L, Maquart F-X, Monboisse JC. Control of melanoma progression by various matrikines from basement membrane macromolecules. Critical Reviews in Oncology/Hematology. 2004 2004/3;49(3):221-3.
32. Schor S.L., Schor A.M. Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res. 2001, 3(6):373-379.
33. Tran KT, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 2004 June 01, 2004;12(3):262-8.
34. Gardi C., Calzoni P., Marcolongo P., Cavarra E., Vanni L., Lungarella G. Collagen breakdown products and lung collagen metabolism: an in vitro study on fibroblast cultures. Thorax 1994 Apr, 49(4):312-318.
35. Adair-Kirk T.L., Senior R.M. Fragments of extracellular matrix as mediators of inflammation. Int. J. Biochem. Cell Biol. 2008, 40(6-7):1101-1110.
36. Xia T., Akers K., Eisen A.Z., Seltzer J.L. Comparison of cleavage site specificity of gelatinase A and B using collagenous peptides. Biochim. Biophys. Acta. 1996, 1293(2):259-266.
37. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 2005 Apr-Jun, 9(2):267-285.
38. Marom B, Rahat MA, Lahat N, Weiss-Cerem L, Kinarty A, Bitterman H. Native and fragmented fibronectin oppositely modulate monocyte secretion of MMP-9. J. Leukoc. Biol. 2007 June 1, 2007;81(6):1466-76.
39. Kuratomi Y., Nomizu M., Tanaka K., Ponce M.L., Komiyama S., Kleinman H.K., et al. Laminin gamma 1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. Br. J. Cancer 2002 Apr 8, 86(7):1169-1173.
40. Kzhyshkowska J, Workman G, Cardo-Vila M, Arap W, Pasqualini R, Gratchev A, et al. Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J. Immunol. 2006 May 15, 2006; 176(10): 5825-32.
41. Shankavaram U.T., DeWitt D.L., Funk S.E., Sage E.H., Wahl L.M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell. Physiol. 1997, 173:327-334.
42. Radauceanu A., Ducki C., Virion J.M., Rossignol P., Mallat Z., McMurray J., et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J. Card. Fail. 2008 Aug, 14(6):467-474.
43. Miller A.D., Tyagi S.C. Mutation in collagen gene induces cardiomyopathy in transgenic mice. J. Cell. Biochem. 2002, 85(2):259-267.
44. Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, et al. Effect of a cleavage-resistant collagen mutation on left ventricular remodeling. Circ Res. 2003 August 8, 2003;93(3):238-45.
45. Trueblood N.A., Xie Z., Communal C., Sam F., Ngoy S., Liaw L., et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ. Res. 2001 May 25, 88(10):1080-1087.
46. Schellings M.W., Vanhoutte D., Swinnen M., Cleutjens J.P., Debets J., van Leeuwen R.E., et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J. Exp. Med. 2009 Jan 16, 206(1):113-123.
47. Blankesteijn W.M., Creemers E., Lutgens E., Cleutjens J.P., Daemen M.J., Smits J.F. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol. Scand. 2001 Sep, 173(1):75-82.
48. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003 August 7, 2003;285(3):H1229-35.
49. Creemers EEJM, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2003 January 1, 2003;284(1):H364-71.
50. Tian H., Cimini M., Fedak P.W.M., Altamentova S., Fazel S., Huang M.-L., et al. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 2007, 43(6):733-743.
51. Weinberg EO, Mirotsou M, Gannon J, Dzau VJ, Lee RT, Pratt RE. Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics. 2003 January 15, 2003;12(2):113-27.
52. Bujak M., Kweon H.J., Chatila K., Li N., Taffet G., Frangogiannis N.G. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J. Am. Coll. Cardiol. 2008, 51(14):1384-1392.
53. Hudson M.P., Armstrong P.W., Ruzyllo W., Brum J., Cusmano L., Krzeski P., et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial. J. Am. Coll. Cardiol. 2006, 48(1):15-20.
54. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006 2006/2/15; 69(3): 677-87.
55. Bannikov G.A., Karelina T.V., Collier I.E., Marmer B.L., Goldberg G.I. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J. Biol. Chem. 2002, 2002/2/11: M110931200.
56. Dufour A., Sampson N.S., Zucker S., Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J. Cell. Physiol. 2008 Dec, 217(3):643-651.
57. Yamamoto D., Takai S., Jin D., Inagaki S., Tanaka K., Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J. Mol. Cell. Cardiol. 2007 Dec, 43(6):670-676.
58. Yu J., Gu Y., Du K.T., Mihardja S., Sievers R.E., Lee R.J. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials 2009 Feb, 30(5):751-756.